International Journal of Pharmacy and Pharmaceutical Sciences <div align="justify"> <div align="justify"> <p>International Journal of Pharmacy and Pharmaceutical Sciences (Int J Pharm Pharm Sci) is a monthly (April 2014 onwards) peer-reviewed, open access journal. IJPPS publishes original research work in the form of original articles or short communications, which contribute significantly to advance scientific knowledge in pharmacy and pharmaceutical sciences. Review articles on the current and trending subject are also considered by the journal provided they match the current research needs and possess scientific impact.</p> <p>The Scope of the journal encompasses the following</p> <ul> <li class="show">Pharmaceutical Technology, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics</li> <li class="show">Pharmacognosy and Natural Product Research</li> <li class="show">Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmaceutical Analysis</li> <li class="show">Pharmacology, Pharmacy Practice, Clinical and Hospital Pharmacy</li> <li class="show">Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics, Pharmacoeconomics</li> </ul> <p>Research outcomes from medical science/case study and biotechnology of pharmaceutical interest are also considered. From March 2016 journal has also started considering hypothesis however the frequency is limited.</p> <p>IJPPS is committed to bring on surface the diligent and hard work of researchers for the betterment of science and society.</p> <br><br></div> </div> Innovare Academic Sciences Pvt Ltd en-US International Journal of Pharmacy and Pharmaceutical Sciences 2656-0097 CURRENT PERSPECTIVES ON APPLICATIONS OF NANOPARTICLES FOR CANCER MANAGEMENT <p>In the realm of cancer diagnostics, imaging and therapeutics, nanocarrier-based drug delivery systems have gained extensive importance owing to their promising attributes and potential to enhance therapeutic effectiveness. The primary area of research revolves around formulating innovative intelligent nanocarriers such as nanoparticles (NPs) which are capable of selectively responding to cancer-specific conditions and efficiently delivering medications to target cells. These nanocarriers, whether operating in a passive or active manner, can transport loaded therapeutic cargos to the tumor site while minimizing drug elimination from the drug delivery systems. This review primarily focuses on presenting recent advancements in the development and utilization of nanoparticles in the treatment of various cancer types, such as pancreatic cancer, prostate cancer, colorectal cancer, cervical cancer, and breast cancer.</p> ROHIT R. BHOSALE BHAGYESH U. JANUGADE DHANASHRI D. CHAVAN VANDANA M. THORAT Copyright (c) 2023 ROHIT R. BHOSALE, BHAGYESH U. JANUGADE, DHANASHRI D. CHAVAN, VANDANA M. THORAT 2023-09-29 2023-09-29 10.22159/ijpps.2023v15i11.49319 A MASS COMPATIBLE UPLC METHOD FOR THE QUANTIFICATION OF IMPURITIES IN FLUTICASONE PROPIONATE NASAL SPRAY <p><strong>Objective: </strong>The objectives of the present study were to develop and validate a mass-compatible ultra-performance liquid chromatography (UPLC) method to quantify the impurities in fluticasone nasal spray, and to establish a suitable container-closure system for the formulation.</p> <p><strong>Methods: </strong>A gradient method was optimized with a flow rate of 0.5 ml/min, detector wavelength-240 nm, run time-25 min and 0.1% Trifluoroacetic acid (TFA) in water as solvent A and Methanol as solvent B.</p> <p><strong>Results: </strong>The developed method was linear over the range of 0.07-1.10 µg/ml for impurity-I, 0.16-2.47 µg/ml for impurity-II, 0.67-10.0 µg/ml for impurity-III, and 1.29-19.3 µg/ml for impurity-IV. The limit of quantification (LOQ) and limit of detection (LOD) were established as 0.07 and 0.02 µg/ml, 0.14 and 0.05 µg/ml, 0.59 and 0.19 µg/ml, 1.06 and 0.35 µg/ml for impurities I-IV respectively. The percent relative standard deviation (%RSD) of the replicate analysis for impurities I-IV, was within the acceptance criteria (0.4, 0.2, 0.3, and 0.1% respectively) that proved the precision of the method. The accuracy of the method was studied from 50%-150% of test concentration and the results ranged from 100.3% to 109.4%. The container-closure compatibility study revealed that the solution stored in the glass container system did not generate any additional peaks in the chromatogram.</p> <p><strong>Conclusion: </strong>Hence, the developed method can be employed by quality testing laboratories to quantify impurities in fluticasone propionate nasal spray. The study also suggests that glass containers could serve as a compatible system for the storage of fluticasone propionate nasal solution.</p> MUGADA RAVI PRASADA RAO RAMA KRISHNA THOTA MAHIBALAN SENTHI PAUL MOGADATI SRINIVAS ARUTLA Copyright (c) 2023 MUGADA RAVI PRASADA RAO, RAMA KRISHNA THOTA, MAHIBALAN SENTHI, PAUL MOGADATI, SRINIVAS ARUTLA 2023-09-01 2023-09-01 50 50 CARDIAC AUTONOMIC DYSFUNCTION IN PATIENTS WITH EPILEPSY <p><strong>Objective</strong>: The objective of this research was to appraise autonomic impairment through the examination of both time-domain and frequency-domain parameters of heart rate variability in individuals with epilepsy.</p> <p><strong>Methods: </strong>Thirty epilepsy patients and thirty healthy subjects were enrolled in our study for evaluation of autonomic functions, which was assessed by comparing heart rate variability between epilepsy patients and healthy subjects.</p> <p><strong>Results: </strong>There was no notable disparity observed in mean heart rate between the two groups. However, the frequency-domain metrics-LF Power, HF Power, and LF/HF ratio exhibited statistically noteworthy differences when comparing the patients to the control group (p-value&lt;0.05). Conversely, parameters such as SDNN, RMSST, and pNN50 did not demonstrate statistically considerable differences in comparison to the controls (p-value&gt;0.05). The parameters did not exhibit statistically significant distinctions between individuals with epilepsy for under 10 y and those diagnosed with epilepsy for over 10 y.</p> <p><strong>Conclusion: </strong>Our investigation revealed a notable contrast in HRV metrics between the patient group and the group of individuals in good health. The potential utilization of HRV as an indicator of susceptibility to SUDEP could enhance the quality of guidance provided to both patients and their families. Additional exploration is warranted, involving more extensive participant cohorts, and examining the impact of antiepileptic medications on HRV, within future studies.</p> RASHMI H. PRAVEEN PANCHAKSHARIMATH ROHITH V. Copyright (c) 2023 RASHMI H., PRAVEEN PANCHAKSHARIMATH, ROHITH V. 2023-10-01 2023-10-01 13 16 10.22159/ijpps.2023v15i10.49095